What is BrainsWay?
Founded in 2003 and headquartered in Jerusalem, Israel, BrainsWay has established itself as a global leader through its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. Developed in collaboration with the National Institute of Health, this technology offers noninvasive treatment options for a range of mental health conditions. BrainsWay is distinguished as the first and only TMS company to achieve three FDA-cleared indications, including major depressive disorder (with anxious depression), obsessive-compulsive disorder, and smoking addiction. The company's innovative platform also shows promise and is utilized for conditions such as bipolar disorders, post-traumatic stress disorders, schizophrenia, chronic pain, and other neurological and psychiatric ailments. BrainsWay serves a broad network of doctors, hospitals, and medical centers across the United States, East Asia, and internationally, operating on both the NASDAQ and Tel Aviv Stock Exchange.
How much funding has BrainsWay raised?
BrainsWay has raised a total of $20M across 1 funding round:
Stock/Share Issuance
$20M
Stock/Share Issuance (2025): $20M, investors not publicly disclosed
What's next for BrainsWay?
The recent major strategic investment signals a pivotal moment for BrainsWay, likely enabling accelerated research and development, expansion into new therapeutic areas, and broader market penetration. With its established FDA clearances and a growing portfolio of treatable conditions, the company is well-positioned to capitalize on the increasing demand for effective, noninvasive mental health solutions. This financing is expected to fuel further innovation in its Deep TMS platform and solidify its leadership in the neurostimulation sector, potentially leading to new indications and enhanced patient care globally.
See full BrainsWay company page
